Waisman Biomanufacturing

GMP Manufacturing

GMP mRNA and LNP Manufacturing

Waisman offers a comprehensive range of platform mRNA and lipid nanoparticle manufacturing solutions, including custom template preparation, several platforms for in vitro transcription, variable scales based on stage of development, and custom lipid nanoparticle formulation to support non-clinical and clinical applications. Waisman has delivered mRNA-LNP products into several pre-IND programs and has the quality systems and production infrastructure to support through Phase 2 human clinical trials. 

GMP mRNA Manufacturing Platform

Comprehensive Services
 

  • CGMP plasmid template preparation
  • mRNA process development, manufacturing, QC testing, and regulatory support
  • Lipid Nanoparticle (LNP) formulation studies, fabrication, and QC testing

Robust Platform Manufacturing Process

  • High yield mRNA in vitro transcription with custom reagent options including 5' capping
  • High encapsulation rate with platform microfluidics equipment
  • Milligram to gram capacity
  • Integrated RNA + LNP and aseptic fill manufacturing processes

 

Phase-Appropriate Analytics

  • Quality Control testing including capping and polyA tail
  • In-house development of custom potency assays

Demonstrated Delivery

  • Non-GMP mRNA-LNP delivered for preclinical research
  • GMP mRNA-LNP delivered for first-in-human clinical trials

mRNA QC Testing

 

AttributeMethod
mRNA IdentitySequencing
 
Purity
mRNA integrity
 
IP-RP-HPLC
 
mRNA concentration
 
UV-Vis
 
5' capping efficiency
 
Custom MS
 
Poly A tail length
 
PAGE
 
pH
 
USP <791>
 
Safety
 

Endotoxin

Bioburden

Sterility

Subvisible particulates

Potency
 
Custom
 

Lipid Nanoparticle Formulation

Comprehensive Services
 

  • Cytiva Ignite in-line mixing platform
  • 10-100 ml batch sizes; potential to scale to 1000 ml
  • Lipid options from a variety of commercial vendor sources
  • Downstream tangential flow filtration (TFF) for custom dosing and final formulation
  • Automated fill/finish with a validated platform aseptic process

Phase-Appropriate Analytics

  • Platform methods for biophysical characteristics
  • In-house development of custom potency assays

Demonstrated Delivery

  • Non-GMP mRNA-LNP delivered for preclinical research
  • Engineering batches delivered for non-human primate studies

RNA-LNP QC Testing

Add table of QC available here

AttributeMethod
 
Lipid Identity
 
HPLC-CAD (contract vendor)
 

Purity (including adduct formation)

mRNA:gRNA ratios
 

IP-RP-HPLC
 
RNA Content
 
Ribogreen
 
Particle size, polydispersity, zeta potential
 
DLS
 
Osmolality
 
USP <785>
 
pH
 
USP <791>
 
Safety
 

Endotoxin

Bioburden

Sterility

Subvisible particulates

Potency
 
Custom
 

 

Scope of Services

RNA-LNP Program Workflow